The content on this site is intended for healthcare professionals only
Prof Meral Beksac (Ankara University Medical School, Ankara, Turkey) and Prof Roman Hájek (University of Ostrava, Ostrava, Czech Republic) discuss results of INTEGRATE study to describe treatment pathways, outcomes and resource use in patients with multiple myeloma in emerging markets.
Initially, Prof Beksac explains the objectives and results of the INTEGRATE study. Prof Hájek then discusses with Prof Beksac the clinical impact and future outcomes of this study. They conclude by discussing the future for multiple myeloma care.
This programme has been supported by an unrestricted educational grant from Takeda
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Hodgkin’s and non-Hodgkin’s lymphomas (NHL)
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC
